Answers are grounded in this paper and cite their sources.
We compared the response to protease inhibitor-containing highly active antiretroviral therapy in 175 HIV-1 treatment-naive patients harbouring subtype B versus non-B. No difference in the proportion of patients with viral loads below 400 copies/ml was observed at month 24. However, there was a significant difference in the median CD4 cell increase at month 24. Whether this is caused by viral or immune factors warrants further investigation. Studies on highly active antiretroviral therapy (HAART) in individuals infected with non-B subtypes are needed to identify potential subtype-specific differences in the response to therapy. We compared the efficacy of a protease inhibitor-containing regimen (with two nucleoside analogues) in treatment-naive patients harbouring either B or non-B subtypes. Reverse transcriptase and protease sequencing was performed using the Viroseq version 2.0 method (Celera Diagnostics, USA) and the TruGene HIV-1 sequencing kit (Bayer Diagnostics, Berkeley, CA, USA), and viral subtyping was done using I-subtyping, the HIV-SEQ program from Stanford University and was confirmed by the subtyping tool from the National Center for Bioinformatics. To evaluate the response to HAART, the proportion of patients achieving a plasma HIV viral load below 400 copies/ml and the absolute CD4 cell count after 6, 12 and 24 months were computed. Baseline demographic and laboratory characteristics were compared between B and non-B groups using chi-square and Fisher exact tests. Wilcoxon/Kruskall–Wallis tests were used for univariate analyses. A multiple linear regression was performed for the CD4 cell count evolution from baseline to month 24. As a result of the non-normality of CD4 cell count variation, this value was square root transformed. The following variables were included in the model: subtype, sex, baseline parameters [viral load, total lymphocyte count (absolute and percentage), CD4 cell count (absolute and percentage), Centers for Disease Control and Prevention stage and drug regimens at treatment initiation]. We identified 175 patients, of whom 56 (32%) were infected by subtype B and 119 (68%) by non-B subtype virus, including subtypes A (21), C (25), D (eight), G (eight), H (two), J (one), recombinant forms (AE seven, AG 22) and mosaics (22). Most B patients were Caucasians (90%) and homosexual (71%), whereas most non-B patients were Africans (89%) and heterosexual (100%). The median baseline viral load (4.9 versus 4.8 log) and CD4 cell count (264 versus 225 cells/mm3) were comparable in both groups. There was no statistical difference in the use of any antiretroviral drug between both groups. There was no difference between the groups in median follow-up (1536 versus 1617 patient-days; P = 0.42). The proportion of patients who achieved undetectable viral load at month 24 was 52% for the B subtype and 64% for the non-B subtype (intent to treat analysis; missing equals failure). The CD4 cell increase at month 24 was significantly lower in the non-B group: +161 versus +235 cells/mm3 (P < 0.02). Among the different non-B subtypes, differences were noted in the CD4 cell response, although none was significant: subtype A: +140; C: +158; circulating recombinant forms (CRF): +165; mosaics: +148; and others +185 cells/mm3. As subtype A had the lowest CD4 cell increase, we compared the CD4 cell response between group B and group AA patients, i.e. 66 patients, harbouring group A, CRF-AG, CRF-AE and mosaics containing at least a part of subtype A. There was a statistically significant difference between B and AA patients in terms of CD4 cell increase at month 24: +235 versus +162 (P < 0.03). At treatment initiation, the viral load was lower in the AA group (4.7 log versus 4.9 log; P < 0.02) and the CD4 cell count was lower, although not statistically significant (211 versus 264 cells/mm3). In multiple linear regression, baseline viral load and the percentage of total lymphocytes were the only variables associated with the CD4 cell variation. Most of the available data on the clinical outcome of HAART in non-B HIV-1 subtypes suggest that patients respond equally well regardless of the subtype. One report [1] has, however, suggested that the subtype may affect the clinical response in the long term but factors such as adherence and psychosocial conditions should be taken into account. Other studies did not confirm these findings [1–4]. Our study, performed in a single centre providing the same therapeutic attitude as well as similar psychosocial support to both B and non-B patients, argues against a role for viral subtypes in treatment responses in terms of viral load. However, the CD4 cell increase at month 24 was significantly lower in the non-B group. Larger CD4 cell increase after HAART initiation have been shown to be associated with higher baseline HIV-1 viral loads [5]. Baseline CD4 cell count also play a role in CD4 cell response, higher baseline CD4 cell count being associated with higher CD4 cell increases [6,7]. In our study, the median viral load at treatment initiation was equivalent in both groups, and baseline CD4 cell level was slightly lower, although not statistically significant, in the non-B patients. Moreover, in multiple linear regression, baseline CD4 cell level was not predictive of CD4 cell response at month 24. We explored the hypothesis that the difference in CD4 cell response could be caused by some specific non-B subtypes. We could not find any statistically significant differences in CD4 cell response among the different non-B subtypes, but showed that patients harbouring subtype A were responsible for all the difference in CD4 cell increase at month 24, although the viral load response did not differ. The same baseline parameters as the global analysis were evaluated and did not influence the CD4 cell response. Differences in CD4 cell response could be caused by viral or host characteristics, which should be further explored. A more rapid depletion of CD4 lymphocytes and higher levels of plasma HIV-1 RNA has been observed in human peripheral blood lymphocyte of severe combined immunodeficient mice infected with A and C-clade HIV-1 isolates in comparison with B-clade-infected mice [8]. However, in a study evaluating viral fitness in vitro in peripheral blood mononuclear cell culture [9], primary CD4 T cells and macrophages from different human donors, decreased fitness of subtype C compared with subtype B was observed. These apparently contradictory findings together with our observations underline the need for robust prospective trials on greater numbers of patients infected with non-B subtypes to establish whether such differences should be taken into account in the clinical setting.
No takes yet. Share an insight, caveat, or question.
Wit et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: